Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dsup mRNA lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Iowa Health Care
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection, Inhalation, Topical
01
Overview
Dsup mRNA lipid nanoparticles are an experimental mRNA-based therapeutic designed to protect healthy tissues from damage caused by ionizing radiation and certain chemotherapeutic agents like bleomycin. The therapy utilizes lipid nanoparticles (LNPs)—specifically a formulation containing KC2, cholesterol, PEG, and DOPE—to deliver mRNA encoding the tardigrade-derived Damage suppressor (Dsup) protein. Once translated in the target cells, the Dsup protein binds to chromatin and physically shields DNA from strand breaks and reactive oxygen species (ROS). Developed by researchers at the University of Iowa Health Care, MIT, and Brigham and Women's Hospital, this approach aims to mitigate the side effects of radiotherapy in cancer patients (such as oral mucositis or proctitis) and prevent bleomycin-induced pulmonary fibrosis by reducing cellular senescence and DNA damage in epithelial tissues.
- Other names
- Dsup mRNA LNPstardigrade Dsup mRNA nanoparticles
02
Targets
DNA
Beyond the preview
Go deeper on Dsup mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dsup mRNA lipid nanoparticles.